Education
About Us
Working with TipRanks
Follow Us
CureVac (CVAC)
NASDAQ:CVAC
CVAC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.37 - $5.28
Previous CloseN/A
Volume1.54M
Average Volume (3M)585.92K
Market Cap
$871.35M
Enterprise ValueN/A
Total Cash (Recent Filing)$554.92M
Total Debt (Recent Filing)€40.13M
Price to Earnings (P/E)5.3
Beta1.24
Next Earnings
Aug 14, 2025EPS Estimate
0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding225,155,870
10 Day Avg. Volume603,796
30 Day Avg. Volume585,920
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)0.83
Price to Sales (P/S)0.00
P/FCF Ratio6.08
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$8.00Price Target Upside86.92% Upside
Rating ConsensusHold
Number of Analyst Covering4
---
CureVac News
PremiumCompany Announcements
CureVac N.V. Reports Q1 2025 Financial Results Amid Strategic Restructuring
PremiumCompany Announcements
CureVac Reports Q1 2025 Financial Results Amid Revenue Decline
PremiumCompany Announcements
CureVac Reports Q1 2025 Financials and Advances in Oncology Pipeline---
Bulls Say, Bears Say
Bulls Say
Financial PositionThe €400M payment from the amended GSK licensing agreement supports the company's financial position.
Patent RulingsThe European Patent Office confirmed the validity of CVAC patent EP 4 023 755 B1, which is a foundational technology for the company.
Trial AdvancementsCVAC announced enrollment completion of the Ph1 Part B trial of CVGBM in resected glioblastoma.
Bears Say
Analyst RatingsThe analyst reiterates an underperform rating due to significant derisking needed for pipeline assets amid restructuring and hesitance on the impact of GSK-partnered assets.
Market CompetitionRoyalty-bearing flu/COVID programs with GSK are unlikely to drive much value due to their late entries into the market.
Pipeline RisksPipeline assets from CureVac are still in the very early stages of development and await clinical proof-of-concept before significant value can be assigned.
---
Ownership Overview
― Insiders
0.08% Mutual Funds
0.21% Other Institutional Investors
98.50% Public Companies and Individual Investors
CVAC FAQ
What was CureVac’s price range in the past 12 months?
CureVac lowest stock price was $2.37 and its highest was $5.28 in the past 12 months.
What is CureVac’s market cap?
CureVac’s market cap is $871.35M.
When is CureVac’s upcoming earnings report date?
CureVac’s upcoming earnings report date is Aug 14, 2025 which is in 84 days.
How were CureVac’s earnings last quarter?
Currently, no data Available
Is CureVac overvalued?
According to Wall Street analysts CureVac’s price is currently Undervalued.
Does CureVac pay dividends?
CureVac does not currently pay dividends.
What is CureVac’s EPS estimate?
CureVac’s EPS estimate is 0.01.
How many shares outstanding does CureVac have?
CureVac has 225,155,870 shares outstanding.
What happened to CureVac’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of CureVac?
Among the largest hedge funds holding CureVac’s share is Platinum Investment Management. It holds CureVac’s shares valued at 0.
---
CureVac Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$8.00 (86.92% Upside)
$8.00 (86.92% Upside)
Blogger Sentiment
Neutral
CVAC Sentiment 50%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 2.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $23.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 3.6%
Last 30 Days ▼ 3.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
25.88%
12-Months-Change
Fundamentals
Return on Equity
28.12%
Trailing 12-Months
Asset Growth
-4.53%
Trailing 12-Months
Company Description
CureVac
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. The company was founded in 2000 and is headquartered in Tübingen, Germany.
---
CVAC Company Deck
---
CVAC Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
CureVac has demonstrated strong financial health with a solid cash runway and strategic partnerships, particularly with GSK. Significant progress in oncology and patent validation are positive indicators. However, operational challenges, including a major restructuring and associated costs, pose concerns.Read More>---
CVAC Stock 12 Month Forecast
Average Price Target
$8.00
▲(86.92% Upside)
Technical Analysis
Xencor
―
Vir Biotechnology
―
Nurix Therapeutics
―
Praxis Precision Medicines
―
AbCellera Biologics
―
---